Increased alpha-synuclein tear fluid levels in patients with Parkinson's disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 05 2020
22 05 2020
Historique:
received:
07
01
2020
accepted:
05
05
2020
entrez:
24
5
2020
pubmed:
24
5
2020
medline:
2
12
2020
Statut:
epublish
Résumé
The objective of the study was to estimate if altered levels of alpha-synuclein can be detected in tear fluid of patients with Parkinson's disease (PD). Therefore, tear fluid samples of 75 PD patients, 75 control subjects and 31 atypical Parkinsonian patients were collected and analyzed in triplicates using an ultra-sensitive single molecule array (SIMOA) system and applying a human alpha-synuclein immunoassay. In PD, levels of total soluble alpha-synuclein were significantly increased compared to control subjects (p = 0.03; AUC PD vs. controls 0.60). There was no difference comparing PD patients stratified by Hoehn & Yahr stages and atypical Parkinsonian syndromes stratified by tauopathies and non-PD-synucleinopathies against each other (p > 0.05). In conclusion, alpha-synuclein can be detected and quantified in tear fluid, revealing small but significant differences in total alpha-synuclein levels between PD and control subjects. Tear fluid can be collected non-invasively and risk-free, therefore presenting a promising source for further biomarker research.
Identifiants
pubmed: 32444780
doi: 10.1038/s41598-020-65503-1
pii: 10.1038/s41598-020-65503-1
pmc: PMC7244583
doi:
Substances chimiques
Biomarkers
0
SNCA protein, human
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8507Références
Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839 (1997).
doi: 10.1038/42166
Eusebi, P. et al. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: A systematic review and meta-analysis. Mov. Disord. 32, 1389–1400 (2017).
doi: 10.1002/mds.27110
Schneider, S. A. et al. Can we use peripheral tissue biopsies to diagnose Parkinson’s disease? A review of the literature. Eur. J. Neurol. 23, 247–261 (2016).
doi: 10.1111/ene.12753
Goldman, J. G. et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson’s disease Features. Mov. Disord. 33, 282–288 (2018).
doi: 10.1002/mds.27232
Vivacqua, G., Mancinelli, R., Belvisi, D., Suppa, A. & Berardelli, A. Detection of α-Synuclein in Saliva: The Importance of Preanalytical Assessment. Mov. Disord. 33, 1029–1030 (2018).
doi: 10.1002/mds.27423
Hamm-Alvarez, S. F. et al. Oligomeric α-synuclein is increased in basal tears of Parkinson’s patients. Biomark. Med. bmm-2019-0167 https://doi.org/10.2217/bmm-2019-0167 (2019).
Bougea, A. et al. Plasma alpha-synuclein levels in patients with Parkinson’s disease: a systematic review and meta-analysis. Neurol. Sci. 40, 929–938 (2019).
doi: 10.1007/s10072-019-03738-1
Ng, A. S. L. et al. Plasma alpha‐synuclein detected by single molecule array is increased in PD. Ann. Clin. Transl. Neurol. 6, 615–619 (2019).
doi: 10.1002/acn3.729
Parnetti, L., Cicognola, C., Eusebi, P. & Chiasserini, D. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson’s diagnosis and prognosis. Biomarkers in Medicine https://doi.org/10.2217/bmm.15.107 (2016).
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. https://doi.org/10.1038/nbt.1641 (2010).
Verde, F. et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 90, 157–164 (2019).
doi: 10.1136/jnnp-2018-318704
Posa, A. et al. Schirmer strip vs. capillary tube method: Non-invasive methods of obtaining proteins from tear fluid. Ann. Anat. https://doi.org/10.1016/j.aanat.2012.10.001 (2013).
Mircheff, A. K. Lacrimal fluid and electrolyte secretion: a review. Curr. Eye Res. 8, 607–17 (1989).
doi: 10.3109/02713688908995761
Hall, S. et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 69, 1445–1452 (2012).
doi: 10.1001/archneurol.2012.1654
Boerger, M. et al. Proteomic analysis of tear fluid reveals disease-specific patterns in patients with Parkinson’s disease – A pilot study. Parkinsonism Relat. Disord. https://doi.org/10.1016/j.parkreldis.2019.03.001 (2019).
Paciotti, S., Bellomo, G., Gatticchi, L. & Parnetti, L. Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as Diagnostic Tools. Front. Neurol. 9, 415 (2018).
doi: 10.3389/fneur.2018.00415
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
doi: 10.1002/mds.26424
Litvan, I. et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47, 1–9 (1996).
doi: 10.1212/WNL.47.1.1
Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496–503 (2013).
doi: 10.1212/WNL.0b013e31827f0fd1
Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670–6 (2008).
doi: 10.1212/01.wnl.0000324625.00404.15